

**DERIVATIVES OF 1,3-DIHYDRO-2H-IMIDAZO[4,5-B]QUINOLINE-2-ONE  
AS AN INHIBITORS OF PHOSPHODIESTERASE, A METHOD OF ITS  
SYNTHESIS, INTERMEDIATE COMPOUNDS, A PHARMACEUTICAL  
COMPOSITION AND A METHOD OF ITS PREPARING**

**Publication number:** RU2127273 (C1)

**Publication date:** 1999-03-10

**Inventor(s):** EHDDI ZHAN EHDGAR FREJNE [BE]; AL FONS EHRMAN  
MARGARETA RAEJM [BE]; DID E ROBER GI GABRIEHL DE  
SHA [BE] +

**Applicant(s):** JANSSEN PHARMACEUTICA NV [BE] +






**Classification:**

**- international:** A61K31/47; A61K31/4738; A61P37/08; C07D215/38;  
C07D233/40; C07D233/72; C07D233/76; C07D233/96;  
C07D401/06; C07D401/10; C07D471/04; A61K31/47;  
A61K31/4738; A61P37/00; C07D215/00; C07D233/00;  
C07D401/00; C07D471/00; (IPC1-7): A61K31/47; C07D215/00;  
C07D215/38; C07D233/00; C07D233/40; C07D233/72;  
C07D233/96; C07D471/04; C07D471/04  
**- European:** C07D215/38; C07D233/76; C07D233/96; C07D401/06;  
C07D401/10; C07D471/04

**Application number:** RU19940019971 19921027

**Priority number(s):** WO1992EP02496 19921027; US19910784955 19911030

**Also published as:**

 EP0541153 (A1)  
 ZA9208373 (A)  
 US5521187 (A)  
 PL170749 (B1)  
 PH31245 (A)

more >>

**Abstract of RU 2127273 (C1)**

**FIELD:** organic chemistry, biochemistry, pharmacy. **SUBSTANCE:** invention relates to derivatives of 1,3-dihydro-2H-imidazo[4,5-b]quinoline-2-one of the formula (I) where R - phenyl possibly substituted with 1-3 substituents taken from halogen, alkyl, or radical =C=O or =C= N-O-R where R is C<SB>1-6</SB>-alkyl possibly substituted with COOH, COO-C<SB>1-4</SB>-alkyl or CON-R<SP>3</SP>R where R is C<SB>1-4</SB>-alkyl and R is C<SB>3-7</SB>-alkyl or R and R taken together with nitrogen atom to which they are bound can form piperazine cycle, or their pharmaceutically acceptable salts, or their stereomeric forms that are able to inhibit activity of phosphodiesterase and can be used for treatment of patients with allergic and atonic sicknesses. **EFFECT:** improved method of synthesis, enhanced effectiveness of compounds. 12 cl, 2 tbl, 25 ex

Data supplied from the *espacenet* database — Worldwide